AwesomeCapital

Bio-Techne EPS misses by $0.09, misses on revenue

Bio-Techne (NASDAQ:TECH): Q4 Non-GAAP EPS of $1.25 misses by $0.09; GAAP EPS of $0.42 misses by $0.35.

Revenue of $191.66M (+6.3% Y/Y) misses by $4.71M.

https://seekingalpha.com/news/3487341-bio-techne-eps-misses-0_09-misses-revenue

Becton, Dickinson FQ3 top-line up 2%

Becton, Dickinson (BDX) Q3 results: Revenues: $4,350M (+1.7%); Medical: $2,311M (+2.9%); Life Sciences: $1,058M (-1.9%); Interventional: $981M (+2.8%).

Net Income: $413M (-25.7%); EPS: $1.51 (-25.6%); Non-GAAP EPS: $3.08 (+5.8%); CF Ops: $1,959M (+25.7%).

Fiscal 2019 Guidance: Revenue growth (reported basis): 8% – 9% (unch); Non-GAAP EPS: $11.65 – 11.75 (unch).

Previously: Becton, Dickinson EPS beats by $0.02, misses on revenue (Aug. 6)

https://seekingalpha.com/news/3487351-becton-dickinson-fq3-top-line-2-percent

Regeneron beats Q2 consensus

Regeneron Pharmaceuticals (REGN) Q2 results: Revenues: $1,933.7M (+20.3%); Net product sales: $1,205.3M (+21.0%); Sanofi collaboration revenue: $349.1M (+46.8%); Bayer collaboration revenue: $289M (+9.9%); Other revenue: $90.3M (-18.6%).

Eylea: $1,875.6M (+13.1%); Libtayo: $40.8M; Arcalyst: $4.2M (-4.5%).

Sanofi-reported sales: Dupixent: $557.3M (+166.4%); Praluent: $73.7M (+0.3%); Kevzara: $58.5M (+142.7%); Zaltrap: $26.6M (-6.3%).

Net Income: $193.1M (-65.0%); EPS: $1.68 (-65.1%); Non-GAAP Net Income: $690M (+10.6%); Non-GAAP EPS: $6.02 (+10.5%).

2019 Guidance: Sanofi collaboration revenue: $500M – 530M from $500M – 535M; CAPEX: $380M – 420M from $410M – 475M.

Previously: Regeneron Pharmaceuticals EPS beats by $0.60, beats on revenue (Aug. 6)

https://seekingalpha.com/news/3487364-regeneron-beats-q2-consensus